Drug Trial Radar · NCT07940166
A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and safety of HRS-8046 in patients with solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of HRS-8046.
Conditions
- Solid Tumor
Interventions
HRS-8046 TabletDrug
HRS-8046 tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: Approximately 2 years.
- Maximum tolerated dose (MTD)Time frame: Approximately 1 year.
- Recommended Phase II Dose (RP2D)Time frame: Approximately 2 years.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)
Nanjing, Jiangsu, China
The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.